Dolutegravir-based regimen for maintenance of viral suppression in people living with HIV: 48‐week results in real life setting.
Keyword(s):
2021 ◽
2018 ◽
Vol 109
(5-6)
◽
pp. 800-809
◽
Keyword(s):
2020 ◽
Vol Publish Ahead of Print
◽
2019 ◽
Vol 41
(4)
◽
pp. 444-451
◽
Keyword(s):
2019 ◽
Vol 6
(Supplement_2)
◽
pp. S476-S476
2019 ◽
Vol 6
(Supplement_2)
◽
pp. S478-S478